73 related articles for article (PubMed ID: 15705654)
21. Stability analysis of mixtures of mutagenetic trees.
Bogojeska J; Lengauer T; Rahnenführer J
BMC Bioinformatics; 2008 Mar; 9():165. PubMed ID: 18366778
[TBL] [Abstract][Full Text] [Related]
22. Modeling cancer progression via pathway dependencies.
Edelman EJ; Guinney J; Chi JT; Febbo PG; Mukherjee S
PLoS Comput Biol; 2008 Feb; 4(2):e28. PubMed ID: 18282083
[TBL] [Abstract][Full Text] [Related]
23. Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.
Kamradt J; Jung V; Wahrheit K; Tolosi L; Rahnenfuehrer J; Schilling M; Walker R; Davis S; Stoeckle M; Meltzer P; Wullich B
PLoS One; 2007 Aug; 2(8):e769. PubMed ID: 17712417
[TBL] [Abstract][Full Text] [Related]
24. Hyperdiploidy defines a distinct cytogenetic entity of meningiomas.
Ketter R; Kim YJ; Storck S; Rahnenführer J; Romeike BF; Steudel WI; Zang KD; Henn W
J Neurooncol; 2007 Jun; 83(2):213-21. PubMed ID: 17225936
[TBL] [Abstract][Full Text] [Related]
25. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
26. Dimension reduction methods for microarrays with application to censored survival data.
Li L; Li H
Bioinformatics; 2004 Dec; 20(18):3406-12. PubMed ID: 15256406
[TBL] [Abstract][Full Text] [Related]
27. Partial Cox regression analysis for high-dimensional microarray gene expression data.
Li H; Gui J
Bioinformatics; 2004 Aug; 20 Suppl 1():i208-15. PubMed ID: 15262801
[TBL] [Abstract][Full Text] [Related]
28. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Vis AN; Schröder FH; van der Kwast TH
Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
[TBL] [Abstract][Full Text] [Related]
29. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
30. Estimating cancer survival and clinical outcome based on genetic tumor progression scores.
Rahnenführer J; Beerenwinkel N; Schulz WA; Hartmann C; von Deimling A; Wullich B; Lengauer T
Bioinformatics; 2005 May; 21(10):2438-46. PubMed ID: 15705654
[TBL] [Abstract][Full Text] [Related]
31. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.
Verma M; Manne U
Crit Rev Oncol Hematol; 2006 Oct; 60(1):9-18. PubMed ID: 16829121
[TBL] [Abstract][Full Text] [Related]
32. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic and molecular aspects of gastric cancer: clinical implications.
Panani AD
Cancer Lett; 2008 Aug; 266(2):99-115. PubMed ID: 18381231
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
